Doctor G Kees Hovingh

Back

Doctor G Kees Hovingh

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))

Member of:

Presentations Articles

Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies

Event: ESC Congress 2017

Topic: Drug therapy

Session: Optimising cardiovascular pharmacotherapy

Access

PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?

Event: ESC Congress 2017

Topic: Lipids (Epidemiology and Prevention)

Session: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

Access

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolaemia

Event: ESC Congress 2016

Topic: Primary cardiovascular prevention: interventions and outcomes

Session: Cardiovascular prevention outcomes I

Access

ESC 365 is supported by

Explore sponsored resources

Doctor G Kees Hovingh Follow

Contributor content

Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies

PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolaemia

ESC 365 is supported by

Doctor G Kees Hovingh